INTRODUCTION: The 5-year survival of metastatic melanoma is < 18%. Historically, treatment options were limited. In 2011, 2 new agents were approved. METHODS: We re-abstracted the medical records of a random sample (n = 520) of metastatic melanoma patients who had been diagnosed in 2011 and reported to population-based registries in the U.S. We also queried their treating physicians. Factors associated with treatment and survival were assessed using logistic and Cox proportional hazards regressions, respectively. RESULTS: 21.4% of patients received no treatment, 20.8% received ipilimumab and 57.5% of patients with BRAF-positive tumors received vemurafenib/dabrafenib. Receipt of ipilimumab was less likely among patients of 75 years or older (vs. < 55 years: odds ratio (OR) 0.32; 95% confidence interval (CI) 0.15-0.66) and patients without private/military insurance. 46.8% of patients received BRAF testing. Receipt of BRAF testing was less likely among patients of 65 years or more and uninsured patients (OR 0.22; 95% CI 0.07-0.65). Receipt of ipilimumab was associated with better survival during the first 18 months after diagnosis (hazard ratio (HR) 0.66; 95% CI 0.51-0.84) and vemurafenib/dabrafenib with better survival during the first 10 months after diagnosis (HR 0.51; 95% CI 0.36-0.73). CONCLUSION: The initial dissemination of ipilimumab and vemurafenib/dabrafenib was limited. Additional research is needed to investigate the apparent lack of long-term survival benefit from these agents.
INTRODUCTION: The 5-year survival of metastatic melanoma is < 18%. Historically, treatment options were limited. In 2011, 2 new agents were approved. METHODS: We re-abstracted the medical records of a random sample (n = 520) of metastatic melanoma patients who had been diagnosed in 2011 and reported to population-based registries in the U.S. We also queried their treating physicians. Factors associated with treatment and survival were assessed using logistic and Cox proportional hazards regressions, respectively. RESULTS: 21.4% of patients received no treatment, 20.8% received ipilimumab and 57.5% of patients with BRAF-positive tumors received vemurafenib/dabrafenib. Receipt of ipilimumab was less likely among patients of 75 years or older (vs. < 55 years: odds ratio (OR) 0.32; 95% confidence interval (CI) 0.15-0.66) and patients without private/military insurance. 46.8% of patients received BRAF testing. Receipt of BRAF testing was less likely among patients of 65 years or more and uninsured patients (OR 0.22; 95% CI 0.07-0.65). Receipt of ipilimumab was associated with better survival during the first 18 months after diagnosis (hazard ratio (HR) 0.66; 95% CI 0.51-0.84) and vemurafenib/dabrafenib with better survival during the first 10 months after diagnosis (HR 0.51; 95% CI 0.36-0.73). CONCLUSION: The initial dissemination of ipilimumab and vemurafenib/dabrafenib was limited. Additional research is needed to investigate the apparent lack of long-term survival benefit from these agents.
Authors: Caroline Robert; Luc Thomas; Igor Bondarenko; Steven O'Day; Jeffrey Weber; Claus Garbe; Celeste Lebbe; Jean-François Baurain; Alessandro Testori; Jean-Jacques Grob; Neville Davidson; Jon Richards; Michele Maio; Axel Hauschild; Wilson H Miller; Pere Gascon; Michal Lotem; Kaan Harmankaya; Ramy Ibrahim; Stephen Francis; Tai-Tsang Chen; Rachel Humphrey; Axel Hoos; Jedd D Wolchok Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245
Authors: Joan L Warren; Eboneé N Butler; Jennifer Stevens; Christopher S Lathan; Anne-Michelle Noone; Kevin C Ward; Linda C Harlan Journal: J Clin Oncol Date: 2014-12-22 Impact factor: 44.544
Authors: Alexander A Parikh; Jamie Robinson; Victor M Zaydfudim; David Penson; Martin A Whiteside Journal: J Surg Oncol Date: 2014-05-09 Impact factor: 3.454
Authors: John M Kirkwood; Ahmad A Tarhini; Monica C Panelli; Stergios J Moschos; Hassane M Zarour; Lisa H Butterfield; Helen J Gogas Journal: J Clin Oncol Date: 2008-07-10 Impact factor: 44.544
Authors: Veronica Di Carlo; Jacques Estève; Christopher Johnson; Fabio Girardi; Hannah K Weir; Reda J Wilson; Pamela Minicozzi; Rosemary D Cress; Charles F Lynch; Karen S Pawlish; Judith R Rees; Michel P Coleman; Claudia Allemani Journal: JNCI Cancer Spectr Date: 2020-09-14
Authors: Lahiru Gangoda; Robyn L Schenk; Lin Tai; Pacman Szeto; Jen G Cheung; Andreas Strasser; Guillaume Lessene; Mark Shackleton; Marco J Herold Journal: Cell Death Dis Date: 2022-04-04 Impact factor: 8.469
Authors: E Jensen-Jarolim; H J Bax; R Bianchini; S Crescioli; T R Daniels-Wells; D Dombrowicz; E Fiebiger; H J Gould; S Irshad; J Janda; D H Josephs; F Levi-Schaffer; L O'Mahony; G Pellizzari; M L Penichet; F Redegeld; F Roth-Walter; J Singer; E Untersmayr; L Vangelista; S N Karagiannis Journal: Allergy Date: 2017-10-05 Impact factor: 13.146
Authors: Ruth P Norris; Rosie Dew; Linda Sharp; Alastair Greystoke; Stephen Rice; Kristina Johnell; Adam Todd Journal: BMC Med Date: 2020-10-23 Impact factor: 8.775